Evidence map›Paper›PMID 21845530›Full record

ArticleCell stress & chaperones2012

Recombinant human Hsp70 protects against lipoteichoic acid-induced inflammation manifestations at the cellular and organismal levels.

Maxim Vinokurov, Vladimir Ostrov, Marina Yurinskaya, David Garbuz, Arkady Murashev, Olga Antonova, Mikhail Evgen'ev

Open access · bronzeAbstract read
In one paragraph

Article in Cell stress & chaperones, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Exogenous Hsp70 delays senescence and improves cognitive function in aging mice.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Maxim VinokurovInstitute of Cell Biophysics of RAS, Pushchino, Moscow Region 142290, Russia.
Vladimir Ostrov
Marina Yurinskaya
David Garbuz
Arkady Murashev
Olga Antonova
Mikhail Evgen'ev
Institute of Cell Biophysics · RUInstitute of Bioorganic Chemistry · RUEngelhardt Institute of Molecular Biology · RUPushchino State Institute of Natural Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been previously reported that pretreatment with exogenous heat shock protein 70 (Hsp70) is able to protect cells and animals from the deleterious effects of bacterial lipopolysaccharide (LPS) produced by Gram-negative bacteria. However, the effects of Hsp70 pretreatment on lipoteichoic acid (LTA) challenge resulted from Gram-positive bacteria infection have not been fully elucidated. In this study, we demonstrated that preconditioning with human recombinant Hsp70 ameliorates various manifestations of systematic inflammation, including reactive oxygen species, TNFα, and CD11b/CD18 adhesion receptor expression induction observed in different myeloid cells after LTA addition. Therefore, exogenous Hsp70 may provide a mechanism for controlling excessive inflammatory responses after macrophage activation. Furthermore, in a rat model of LTA-induced sepsis, we demonstrated that prophylactic administration of exogenous human Hsp70 significantly exacerbated numerous homeostatic and hemodynamic disturbances induced by LTA challenge and partially normalized the coagulation system and multiple biochemical blood parameters, including albumin and bilirubin concentrations, which were severely disturbed after LTA injections. Importantly, prophylactic intravenous injection of Hsp70 before LTA challenge significantly reduced mortality rates. Thus, exogenous mammalian Hsp70 may serve as a powerful cellular defense agent against the deleterious effects of bacterial pathogens, such as LTA and LPS. Taken together, our findings reveal novel functions of this protein and establish exogenous Hsp70 as a promising pharmacological agent for the prophylactic treatment of various types of sepsis.

Indexed as

LipopolysaccharidesTeichoic AcidsAnimalsApoptosisBilirubinCD11b AntigenCD18 AntigensCells, CulturedHemodynamicsHSP70 Heat-Shock ProteinsHumansInflammationMaleMonocytesNeutrophilsRatsBilirubinCD11b AntigenCD18 AntigensHSP70 Heat-Shock ProteinsLipopolysaccharideslipoteichoic acidReactive Oxygen SpeciesRecombinant ProteinsSerum AlbuminTeichoic AcidsTumor Necrosis Factor-alpha

Identifiers

PMID21845530
PMCPMC3227847
OpenAlexW1977220348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.